Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline October 29, 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million October 29, 2025
Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ October 21, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
TransCode Therapeutics to acquire Polynoma and use $25M funds by CK Life Sciences to advance TTX-MC138 into Ph 2 trial October 16, 2025
Xintela’s oncology subsidiary, Targinta AB, and MSK’s Therapeutics Accelerator to develop integrin α10β1 antibody therapeutic in patients with aggressive sarcoma October 15, 2025
Tessera Therapeutics Awarded up to $41.3M from ARPA-H to Advance In Vivo CAR-T Therapies October 15, 2025
AstraZeneca announces agreement with US Government to lower the cost of medicines for American patients October 15, 2025
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics October 15, 2025
Tempus Selected by HHS Agency to Provide Services for Precision Cancer Therapy Program October 15, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 15, 2025
Kincell Bio announces collaboration to advance Moonlight Bio’s lead cell therapy candidate to clinical study October 15, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 8, 2025
Pfizer Reaches Landmark Agreement with the US Government to Lower Drug Costs for American Patients October 8, 2025
Trogenix announces £70M/$95M Series A financing to drive clinical development of potentially curative therapies for aggressive cancers October 7, 2025
Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of RRMM Announced October 7, 2025
